BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 2015;16:897-907. [PMID: 26156651 DOI: 10.1016/S1470-2045(15)00006-6] [Cited by in Crossref: 253] [Cited by in F6Publishing: 151] [Article Influence: 36.1] [Reference Citation Analysis]
Number Citing Articles
1 Rugo HS, Di Palma JA, Tripathy D, Bryce R, Moran S, Olek E, Bosserman L. The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Res Treat 2019;175:5-15. [PMID: 30671765 DOI: 10.1007/s10549-018-05102-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 8.3] [Reference Citation Analysis]
2 Fenchel K, Dale SP, Dempke WC. Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC-are we making progress? Transl Lung Cancer Res 2016;5:373-6. [PMID: 27652201 DOI: 10.21037/tlcr.2016.07.01] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
3 Nie X, Zhang P, Gao JY, Cheng G, Liu W, Li L. Sarcopenia as a predictor of initial administration dose of afatinib in patients with advanced non-small cell lung cancer. Thorac Cancer 2021;12:1824-30. [PMID: 33951292 DOI: 10.1111/1759-7714.13934] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Ibi T, Usuda J, Inoue T, Sato A, Takegahara K. Klotho expression is correlated to molecules associated with epithelial-mesenchymal transition in lung squamous cell carcinoma. Oncol Lett 2017;14:5526-32. [PMID: 29142604 DOI: 10.3892/ol.2017.6862] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
5 Lim JS, Soo RA. Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence. Ther Adv Respir Dis 2016;10:444-54. [PMID: 27480166 DOI: 10.1177/1753465816661091] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
6 Blumenthal GM, Zhang L, Zhang H, Kazandjian D, Khozin S, Tang S, Goldberg K, Sridhara R, Keegan P, Pazdur R. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis. JAMA Oncol 2017;3:e171029. [PMID: 28617920 DOI: 10.1001/jamaoncol.2017.1029] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
7 Bronte G, Franchina T, Alù M, Sortino G, Celesia C, Passiglia F, Savio G, Laudani A, Russo A, Picone A, Rizzo S, De Tursi M, Gambale E, Bazan V, Natoli C, Blasi L, Adamo V, Russo A. The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status. Oncotarget 2016;7:35803-12. [PMID: 26993607 DOI: 10.18632/oncotarget.8130] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sato M, Matsui A, Shimoyama Y, Omote N, Morise M, Hase T, Tanaka I, Suzuki K, Hasegawa Y. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib. Intern Med 2018;57:3429-32. [PMID: 30101911 DOI: 10.2169/internalmedicine.0999-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
9 Hamada A, Suda K, Koga T, Fujino T, Nishino M, Ohara S, Chiba M, Shimoji M, Takemoto T, Soh J, Uchida T, Mitsudomi T. In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial. Lung Cancer 2021;162:79-85. [PMID: 34741886 DOI: 10.1016/j.lungcan.2021.10.014] [Reference Citation Analysis]
10 Prabhash K. Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update. South Asian J Cancer 2019;8:1-17. [PMID: 30766843 DOI: 10.4103/sajc.sajc_227_18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
11 Jin Y, Jiang Q, Xin T. Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab. Thorac Cancer 2018;9:164-6. [PMID: 29027754 DOI: 10.1111/1759-7714.12522] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
12 Aggarwal C, Borghaei H. Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. Oncologist 2017;22:700-8. [PMID: 28408617 DOI: 10.1634/theoncologist.2016-0345] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
13 Song J, Tian J, Zhang L, Qu X, Qian W, Zheng B, Zhang L, Zhao J, Niu M, Zhou M, Cui L, Liu Y, Zhao M. Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma. Eur Radiol 2019;29:2388-98. [PMID: 30643941 DOI: 10.1007/s00330-018-5912-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
14 Polo V, Pasello G, Frega S, Favaretto A, Koussis H, Conte P, Bonanno L. Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization. Oncotarget 2016;7:25050-63. [PMID: 26933818 DOI: 10.18632/oncotarget.7732] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
15 Spicer J, Irshad S, Ang JE, Enting D, Kristeleit R, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2017;79:17-27. [PMID: 27872953 DOI: 10.1007/s00280-016-3189-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
16 Pignata M, Chouaid C, Le Lay K, Luciani L, McConnachie C, Gordon J, Roze S. Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France. Clinicoecon Outcomes Res 2017;9:655-68. [PMID: 29123418 DOI: 10.2147/CEOR.S136657] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
17 Sogawa R, Saita T, Yamamoto Y, Kimura S, Narisawa Y, Kimura S, Shin M. Development of a competitive enzyme-linked immunosorbent assay for therapeutic drug monitoring of afatinib. J Pharm Anal 2019;9:49-54. [PMID: 30740257 DOI: 10.1016/j.jpha.2018.09.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
18 Sun L, Xiong Z, Han C. [Research Advances of Pan-negative Type of Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2018;21:129-38. [PMID: 29526181 DOI: 10.3779/j.issn.1009-3419.2018.02.07] [Reference Citation Analysis]
19 Vengoji R, Macha MA, Nimmakayala RK, Rachagani S, Siddiqui JA, Mallya K, Gorantla S, Jain M, Ponnusamy MP, Batra SK, Shonka N. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. J Exp Clin Cancer Res 2019;38:266. [PMID: 31215502 DOI: 10.1186/s13046-019-1264-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
20 Li Y, Xu H, Su S, Ye J, Chen J, Jin X, Lin Q, Zhang D, Ye C, Chen C. Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma. PLoS One 2017;12:e0183331. [PMID: 28829813 DOI: 10.1371/journal.pone.0183331] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
21 Economopoulou P, Mountzios G. The emerging treatment landscape of advanced non-small cell lung cancer. Ann Transl Med 2018;6:138. [PMID: 29862227 DOI: 10.21037/atm.2017.11.07] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
22 Morabito A. Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients? BMC Med 2018;16:24. [PMID: 29448944 DOI: 10.1186/s12916-018-1011-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
23 Zhuang J, Yu Y, Li Z, Lu S. Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis. Oncotarget 2017;8:53675-83. [PMID: 28881841 DOI: 10.18632/oncotarget.15726] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
24 Li Q, Ma W, Li T. Sortilin as a new membrane inhibitor of EGFR trafficking for overcoming resistance to EGFR inhibitors in non-small cell lung cancer. J Thorac Dis 2018;10:S3186-91. [PMID: 30430029 DOI: 10.21037/jtd.2018.08.25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Pasello G, Vicario G, Zustovich F, Oniga F, Gori S, Rosetti F, Bonetti A, Favaretto A, Toso S, Redelotti R, Santo A, Bernardi D, Giovanis P, Oliani C, Calvetti L, Gatti C, Palazzolo G, Baretta Z, Bortolami A, Bonanno L, Basso M, Menis J, Corte DD, Frega S, Guarneri V, Conte P; Veneto Oncology Network. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study). Oncologist 2019;24:e318-26. [PMID: 30846513 DOI: 10.1634/theoncologist.2018-0712] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
26 Liao BC, Lin CC, Yang JC. Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. Curr Oncol Rep 2017;19:4. [PMID: 28138934 DOI: 10.1007/s11912-017-0560-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
27 Lilienthal I, Herold N. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. Int J Mol Sci 2020;21:E6885. [PMID: 32961800 DOI: 10.3390/ijms21186885] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
28 Wang C, Li Y, Ke L, Cao L, Fan P, Wu Z, Wu Q. The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. J Cancer 2019;10:885-92. [PMID: 30854094 DOI: 10.7150/jca.27528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
29 Daaboul N, Nicholas G, Laurie SA. Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview. Curr Oncol 2018;25:S77-85. [PMID: 29910650 DOI: 10.3747/co.25.3792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
30 Patil V, Joshi A, Noronha V, Agarwala V, Chougule A, Kanan S, Bhattacharjee A, Chandrasekharan A, Pande N, Simha V, Goud S, More S, Kumar R, Mahajan A, Janu A, Purandare N, Prabhash K. Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer. Oncotarget 2019;10:6297-307. [PMID: 31695838 DOI: 10.18632/oncotarget.27214] [Reference Citation Analysis]
31 Roviello G. The distinctive nature of adenocarcinoma of the lung. Onco Targets Ther 2015;8:2399-406. [PMID: 26366094 DOI: 10.2147/OTT.S89225] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
32 Le T, Gerber DE. Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used? Cancers (Basel). 2019;11. [PMID: 30875928 DOI: 10.3390/cancers11030366] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
33 Lee CS, Sharma S, Miao E, Mensah C, Sullivan K, Seetharamu N. A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity. Lung Cancer (Auckl) 2020;11:73-103. [PMID: 33117017 DOI: 10.2147/LCTT.S258444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Brueckl WM, Achenbach HJ, Ficker JH, Schuette W. Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study. BMC Cancer 2018;18:333. [PMID: 29587656 DOI: 10.1186/s12885-018-4208-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
35 Wu M, Hong G, Chen Y, Ye L, Zhang K, Cai K, Yang H, Long X, Gao W, Li H. Personalized drug testing in a patient with non-small-cell lung cancer using cultured cancer cells from pleural effusion. J Int Med Res 2020;48:300060520955058. [PMID: 32954884 DOI: 10.1177/0300060520955058] [Reference Citation Analysis]
36 Tsironis G, Ziogas DC, Kyriazoglou A, Lykka M, Koutsoukos K, Bamias A, Dimopoulos MA. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore? Ann Transl Med. 2018;6:143. [PMID: 29862232 DOI: 10.21037/atm.2018.02.18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
37 Kannaiyan R, Mahadevan D. A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Rev Anticancer Ther 2018;18:1249-70. [PMID: 30259761 DOI: 10.1080/14737140.2018.1527688] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 14.3] [Reference Citation Analysis]
38 Yufen X, Binbin S, Wenyu C, Jialiang L, Xinmei Y. The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer. Springerplus 2016;5:1244. [PMID: 27536527 DOI: 10.1186/s40064-016-2873-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
39 Yoo SH, Ryu JA, Kim SR, Oh SY, Jung GS, Lee DJ, Kwak BG, Nam YH, Kim KH, Yang YJ. Afatinib-Induced Acute Fatal Pneumonitis in Metastatic Lung Adenocarcinoma. Korean J Fam Med 2016;37:351-5. [PMID: 27900074 DOI: 10.4082/kjfm.2016.37.6.351] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
40 Wang X, Goldstein D, Crowe PJ, Yang JL. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. Onco Targets Ther 2016;9:5461-73. [PMID: 27660463 DOI: 10.2147/OTT.S94745] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
41 Komiya T, Yamamoto S, Roy A, McDonald P, Perez RP. Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics. Transl Lung Cancer Res 2017;6:600-10. [PMID: 29114475 DOI: 10.21037/tlcr.2017.07.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
42 Armoiry X, Tsertsvadze A, Connock M, Royle P, Melendez-Torres GJ, Souquet PJ, Clarke A. Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis. PLoS One 2018;13:e0199575. [PMID: 30044785 DOI: 10.1371/journal.pone.0199575] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
43 Sonehara K, Kobayashi T, Tateishi K, Morozumi N, Yoshiike F, Hachiya T, Ono Y, Takasuna K, Agatsuma T, Masubuchi T, Matsuo A, Tanaka H, Morikawa A, Hanaoka M, Koizumi T. Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group. Thorac Cancer 2019;10:1078-85. [PMID: 31006178 DOI: 10.1111/1759-7714.13047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
44 Haslam A, Herrera-Perez D, Gill J, Prasad V. Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials. JAMA Netw Open 2020;3:e200363. [PMID: 32129865 DOI: 10.1001/jamanetworkopen.2020.0363] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
45 Zhu J, Yang Q, Xu W. Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective. Pharmaceutics 2021;13:1500. [PMID: 34575576 DOI: 10.3390/pharmaceutics13091500] [Reference Citation Analysis]
46 Lee Y, Lee KH, Lee GK, Lee SH, Lim KY, Joo J, Go YJ, Lee JS, Han JY. Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. Cancer Res Treat 2017;49:1001-11. [PMID: 28111428 DOI: 10.4143/crt.2016.546] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
47 Lee CS, Milone M, Seetharamu N. Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data. Onco Targets Ther 2021;14:4579-97. [PMID: 34471361 DOI: 10.2147/OTT.S227032] [Reference Citation Analysis]
48 Wang LY, Cui JJ, Guo AX, Yin JY. Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients. Onco Targets Ther 2018;11:529-38. [PMID: 29416353 DOI: 10.2147/OTT.S136579] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
49 Miyashita Y, Ko R, Shimada N, Mitsuishi Y, Miura K, Matsumoto N, Asao T, Shukuya T, Shibayama R, Koyama R, Takahashi K. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. Thorac Cancer 2021;12:329-38. [PMID: 33219754 DOI: 10.1111/1759-7714.13742] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Hirsh V. New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. Onco Targets Ther 2017;10:2513-26. [PMID: 28546756 DOI: 10.2147/OTT.S104177] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
51 Fujita K, Morishima Y, Aida Y, Tsunoda Y, Hida N, Shiozawa T, Nakazawa K, Sekine I, Hizawa N. Afatinib-Induced Severe Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy: A Case Report. J Thorac Oncol 2017;12:e11-3. [PMID: 27780779 DOI: 10.1016/j.jtho.2016.10.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
52 Juan O, Popat S. Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. Ther Adv Med Oncol 2017;9:201-16. [PMID: 28344665 DOI: 10.1177/1758834016687262] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
53 Fu JY, Wan YL, Huang TY, Wu CF, Liu YH, Hsieh MJ, Wu YC, Wu CY. Correlation between image characteristics and pathologic findings in non small cell lung cancer patients after anatomic resection. PLoS One 2018;13:e0206386. [PMID: 30379929 DOI: 10.1371/journal.pone.0206386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
54 Lu W, Chen H, Liang B, Ou C, Zhang M, Yue Q, Xie J. Integrative Analyses and Verification of the Expression and Prognostic Significance for RCN1 in Glioblastoma Multiforme. Front Mol Biosci 2021;8:736947. [PMID: 34722631 DOI: 10.3389/fmolb.2021.736947] [Reference Citation Analysis]
55 Chen Z, Huang W, Tian T, Zang W, Wang J, Liu Z, Li Z, Lai Y, Jiang Z, Gao J, Shen L. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. J Hematol Oncol 2018;11:20. [PMID: 29433585 DOI: 10.1186/s13045-018-0563-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
56 Steeghs EM, Groen HJ, Schuuring E, Aarts MJ, Damhuis RA, Voorham QJ, consortium P, Ligtenberg MJ, Grünberg K. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.04.001] [Reference Citation Analysis]
57 Lazzari C, Bulotta A, Ducceschi M, Viganò MG, Brioschi E, Corti F, Gianni L, Gregorc V. Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer. Front Med (Lausanne) 2017;4:4. [PMID: 28168189 DOI: 10.3389/fmed.2017.00004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
58 Sacher AG, Le LW, Lara-Guerra H, Waddell TK, Sakashita S, Chen Z, Kim L, Zhang T, Kamel-Reid S, Salvarrey A, Darling G, Yasufuku K, Keshavjee S, de Perrot M, Shepherd FA, Liu G, Tsao MS, Leighl NB. A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. Oncotarget 2016;7:25632-9. [PMID: 27028852 DOI: 10.18632/oncotarget.8350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
59 Jibiki T, Nishimura H, Sengoku S, Kodama K. Regulations, Open Data and Healthcare Innovation: A Case of MSK-IMPACT and Its Implications for Better Cancer Care. Cancers (Basel) 2021;13:3448. [PMID: 34298662 DOI: 10.3390/cancers13143448] [Reference Citation Analysis]
60 Bertaglia V, Vallone S, Pacchiana MV, Novello S. Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey. Lung Cancer Manag 2017;6:93-107. [PMID: 30643575 DOI: 10.2217/lmt-2017-0011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
61 He SY, Lin QF, Chen J, Yu GP, Zhang JL, Shen D. Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report. World J Clin Cases 2021; 9(6): 1329-1335 [PMID: 33644199 DOI: 10.12998/wjcc.v9.i6.1329] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 O'Brien MER, Sarker D, Bhosle J, Thillai K, Yap TA, Uttenreuther-Fischer M, Pemberton K, Jin X, Wiebe S, de Bono J, Spicer J. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2018;82:757-66. [PMID: 30088048 DOI: 10.1007/s00280-018-3661-1] [Reference Citation Analysis]
63 König D, Savic Prince S, Rothschild SI. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers (Basel) 2021;13:804. [PMID: 33671873 DOI: 10.3390/cancers13040804] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
64 Germonpré P, Van den Wyngaert T. Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability. PLoS One 2019;14:e0215135. [PMID: 30973926 DOI: 10.1371/journal.pone.0215135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
65 Tien Y, Tsai CL, Hou WH, Chiang Y, Hsu FM, Tsai YC, Cheng JC. Targeting human epidermal growth factor receptor 2 enhances radiosensitivity and reduces the metastatic potential of Lewis lung carcinoma cells. Radiat Oncol 2020;15:58. [PMID: 32143669 DOI: 10.1186/s13014-020-01493-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Fidler MJ, Frankenberger C, Seto R, Lobato GC, Fhied CL, Sayidine S, Basu S, Pool M, Karmali R, Batus M, Lie WR, Hayes D, Mistry J, Bonomi P, Borgia JA. Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy. Oncotarget 2017;8:58108-21. [PMID: 28938541 DOI: 10.18632/oncotarget.17510] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
67 Raju GK, Khozin S, Gurumurthi K, Domike R, Woodcock J. Patient-Centered Approach to Benefit-Risk Characterization Using Number Needed to Benefit and Number Needed to Harm: Advanced Non-Small-Cell Lung Cancer. JCO Clin Cancer Inform 2020;4:769-83. [PMID: 32853030 DOI: 10.1200/CCI.19.00103] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Hiret S, Isambert N, Gomez-Roca C, Bennouna J, Sassi M, de Mont-Serrat H, Fan J, Schnell D, Delord JP. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors. Invest New Drugs 2018;36:1044-59. [PMID: 29808308 DOI: 10.1007/s10637-018-0601-1] [Reference Citation Analysis]
69 Shen J, Liu J, Li H, Bai L, Du Z, Geng R, Cao J, Sun P, Tang Z. Explore association of genes in PDL1/PD1 pathway to radiotherapy survival benefit based on interaction model strategy. Radiat Oncol 2021;16:223. [PMID: 34794456 DOI: 10.1186/s13014-021-01951-x] [Reference Citation Analysis]
70 Mohindra NA, Patel JD. Towards manageable toxicities from targeted lung cancer treatment. Lung Cancer Management 2015;4:279-87. [DOI: 10.2217/lmt.15.30] [Reference Citation Analysis]
71 Simbolo M, Vicentini C, Ruzzenente A, Brunelli M, Conci S, Fassan M, Mafficini A, Rusev B, Corbo V, Capelli P, Bria E, Pedron S, Turri G, Lawlor RT, Tortora G, Bassi C, Guglielmi A, Scarpa A. Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. Sci Rep. 2018;8:7119. [PMID: 29740198 DOI: 10.1038/s41598-018-25669-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
72 Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC. Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. JAMA Oncol 2018;4:1189-97. [PMID: 29902295 DOI: 10.1001/jamaoncol.2018.0775] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
73 Wang P, Zhu M, Zhang D, Guo XG, Zhao S, Zhang XL, Wang DL, Liu CT. The relationship between chronic obstructive pulmonary disease and non-small cell lung cancer in the elderly. Cancer Med 2019;8:4124-34. [PMID: 31184445 DOI: 10.1002/cam4.2333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
74 Bai J, Guo F, Li M, Li Y, Lei X. Click-based amplification: designed to facilitate various target labelling modes with ultralow background amplification. RSC Chem Biol 2021;2:906-16. [PMID: 34458817 DOI: 10.1039/d1cb00002k] [Reference Citation Analysis]
75 Liu Z, Chen Z, Wang J, Zhang M, Li Z, Wang S, Dong B, Zhang C, Gao J, Shen L. Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance. J Hematol Oncol 2018;11:109. [PMID: 30157900 DOI: 10.1186/s13045-018-0651-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
76 Harvey RD, Adams VR, Beardslee T, Medina P. Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. J Oncol Pharm Pract 2020;26:1461-74. [PMID: 32567494 DOI: 10.1177/1078155220931926] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
77 Lu S. Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib. Onco Targets Ther 2019;12:1521-38. [PMID: 30863118 DOI: 10.2147/OTT.S188296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
78 Tan WL, Ng QS. The continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung. Transl Lung Cancer Res 2016;5:106-9. [PMID: 26958503 DOI: 10.3978/j.issn.2218-6751.2015.10.12] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
79 Bombardelli L, Berns A. The steady progress of targeted therapies, promising advances for lung cancer. Ecancermedicalscience 2016;10:638. [PMID: 27350784 DOI: 10.3332/ecancer.2016.638] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
80 Deeks ED, Keating GM. Afatinib in advanced NSCLC: a profile of its use. Drugs Ther Perspect 2018;34:89-98. [PMID: 29540977 DOI: 10.1007/s40267-018-0482-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
81 Abdel Karim N, Kelly K. Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. Oncologist 2019;24:1270-84. [PMID: 30914465 DOI: 10.1634/theoncologist.2018-0112] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
82 Cheng Y, Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, He J, Shi Y, Chen W, Wang X, Luo Y, Nan K, Jin F, Li B, Zhu J. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial. Cancer Med 2020;9:2621-30. [PMID: 32064794 DOI: 10.1002/cam4.2913] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
83 Levy B, Barlesi F, Paz-ares L, Bennouna J, Erman M, Felip E, Isla D, Ryun Kim H, Kim S, Madelaine J, Molinier O, Özgüroğlu M, Rodríguez Abreu D, Adeniji A, Lorence RM, Voccia I, Chisamore MJ, Riess JW. Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.01.023] [Reference Citation Analysis]
84 Buffoni L, Vavalà T, Novello S. Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward? Curr Treat Options Oncol 2016;17:54. [PMID: 27523606 DOI: 10.1007/s11864-016-0429-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
85 Nakao K, Kobuchi S, Marutani S, Iwazaki A, Tamiya A, Isa S, Okishio K, Kanazu M, Tamiya M, Hirashima T, Imai K, Sakaeda T, Atagi S. Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer. Sci Rep 2019;9:18202. [PMID: 31796841 DOI: 10.1038/s41598-019-54804-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
86 Gao M, Zhou Q. [Progress in Treatment of Advanced Squamous Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2020;23:866-74. [PMID: 32798441 DOI: 10.3779/j.issn.1009-3419.2020.101.35] [Reference Citation Analysis]
87 Morin-Ben Abdallah S, Hirsh V. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib. Front Oncol 2017;7:97. [PMID: 28560182 DOI: 10.3389/fonc.2017.00097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
88 Taniguchi Y, Matsumoto Y, Furukawa R, Ohara S, Usui K. The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations. Int J Clin Oncol 2018;23:452-7. [PMID: 29446042 DOI: 10.1007/s10147-017-1233-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
89 Boolell V, Alamgeer M, Watkins DN, Ganju V. The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers (Basel) 2015;7:1815-46. [PMID: 26371045 DOI: 10.3390/cancers7030864] [Reference Citation Analysis]
90 Yonesaka K, Kudo K, Nishida S, Takahama T, Iwasa T, Yoshida T, Tanaka K, Takeda M, Kaneda H, Okamoto I, Nishio K, Nakagawa K. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. Oncotarget 2015;6:33602-11. [PMID: 26418897 DOI: 10.18632/oncotarget.5286] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
91 Pulito C, Cristaudo A, Porta C, Zapperi S, Blandino G, Morrone A, Strano S. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res 2020;39:210. [PMID: 33028357 DOI: 10.1186/s13046-020-01715-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
92 Takeuchi S, Okuda S. Knowledge base toward understanding actionable alterations and realizing precision oncology. Int J Clin Oncol 2019;24:123-30. [PMID: 30542800 DOI: 10.1007/s10147-018-1378-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
93 Keating GM. Afatinib: A Review in Advanced Non-Small Cell Lung Cancer. Target Oncol 2016;11:825-35. [PMID: 27873136 DOI: 10.1007/s11523-016-0465-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
94 Lee SM, Upadhyay S, Lewanski C, Falk S, Skailes G, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Rudd R, Ngai Y, Edwards A, Hackshaw A. The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy. Eur J Cancer 2019;120:86-96. [PMID: 31499384 DOI: 10.1016/j.ejca.2019.07.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
95 Chinese Society of Lung Cancer, Chinese Anti-Cancer Association. [EGFR-TKI ADR Management Chinese Expert Consensus]. Zhongguo Fei Ai Za Zhi 2019;22:57-81. [PMID: 30827323 DOI: 10.3779/j.issn.1009-3419.2019.02.01] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
96 Lewis WE, Hong L, Mott FE, Simon G, Wu CC, Rinsurongkawong W, Lee JJ, Lam VK, Heymach JV, Zhang J, Le X. Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations. JTO Clin Res Rep 2021;2:100237. [PMID: 34820641 DOI: 10.1016/j.jtocrr.2021.100237] [Reference Citation Analysis]
97 Kim L, Saieg M, Di Maio M, Gallo C, Butts C, Ciardiello F, Feld R, Cheng D, Gebbia V, Burgio MA, Alam Y, Signoriello S, Rossi A, Leighl N, Maione P, Morabito A, Liu G, Tsao MS, Perrone F, Gridelli C. Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. Oncotarget 2017;8:57528-36. [PMID: 28915692 DOI: 10.18632/oncotarget.15725] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
98 Puliafito I, Esposito F, Raciti G, Giuffrida P, Caltavuturo C, Colarossi C, Munao S, Sciacca D, Giuffrida D. Metabolic complete tumor response in a patient with epidermal growth factor receptor mutant non-small cell lung cancer treated with a reduced dose of afatinib. J Int Med Res 2022;50:3000605211058864. [PMID: 35291829 DOI: 10.1177/03000605211058864] [Reference Citation Analysis]
99 Zhang J, Zhang Y, Tang S, Jiang L, He Q, Hamblin LT, He J, Xu Z, Wu J, Chen Y, Liang H, Chen D, Huang Y, Wang X, Deng K, Jiang S, Zhou J, Xu J, Chen X, Liang W, He J. Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. BMJ Open 2018;8:e017240. [PMID: 30206071 DOI: 10.1136/bmjopen-2017-017240] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
100 Bahleda R, Varga A, Bergé Y, Soria JC, Schnell D, Tschoepe I, Uttenreuther-Fischer M, Delord JP. Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. Br J Cancer 2018;118:344-52. [PMID: 29337963 DOI: 10.1038/bjc.2017.436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
101 Perdrizet K, Sutradhar R, Li Q, Liu N, Earle CC, Leighl NB. Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada. J Thorac Dis 2021;13:5419-29. [PMID: 34659808 DOI: 10.21037/jtd-21-804] [Reference Citation Analysis]
102 Vatu BI, Cristian T, Artene S, Stiuca A. Long Term Survivor with Erlotinib in Metastatic Lung Cancer-Squamous Cell Carcinoma Subtype. Curr Health Sci J 2020;46:300-4. [PMID: 33304633 DOI: 10.12865/CHSJ.46.03.13] [Reference Citation Analysis]
103 Lu S, Li W, Zhou C, Hu CP, Qin S, Cheng G, Feng J, Wang J, Cseh A, Peil B, Gibson N, Ehrnrooth E, Zhang L. Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung. Onco Targets Ther 2018;11:8565-73. [PMID: 30573970 DOI: 10.2147/OTT.S161506] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
104 Khrystolubova N, Shieh M, Patel AJ, Bailey R. Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting. J Oncol Pharm Pract 2020;26:13-22. [PMID: 30832554 DOI: 10.1177/1078155219833441] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
105 Goss GD, Spaans JN. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung. Oncologist 2016;21:205-13. [PMID: 26768483 DOI: 10.1634/theoncologist.2015-0209] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
106 Ho GF, Chai CS, Alip A, Wahid MIA, Abdullah MM, Foo YC, How SH, Zaatar A, Lam KS, Leong KW, Low JS, Yusof MM, Lee EC, Toh YY, Liam CK. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. BMC Cancer. 2019;19:896. [PMID: 31500587 DOI: 10.1186/s12885-019-6107-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
107 Barnfield PC, Ellis PM. Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations. Drugs 2016;76:1321-36. [PMID: 27557830 DOI: 10.1007/s40265-016-0628-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
108 Leipert J, Hammerschmidt S, Geßner C. Medikamentöse Therapie des metastasierten nicht-kleinzelligen Lungenkarzinoms. Pneumologe 2019;16:397-409. [DOI: 10.1007/s10405-019-00284-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
109 Liu X, Ma B, Li T, Zhao L. Case Report: Afatinib-Induced Interstitial Pneumonia: Experiences and Lessons From Two Patients. Front Pharmacol 2021;12:698447. [PMID: 34721009 DOI: 10.3389/fphar.2021.698447] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Cruz-Ramos M, Zamudio-Cuevas Y, Medina-Luna D, Martínez-Flores K, Martínez-Nava G, Fernández-Torres J, López-Reyes A, Solca F. Afatinib is active in osteosarcoma in osteosarcoma cell lines. J Cancer Res Clin Oncol 2020;146:1693-700. [PMID: 32333142 DOI: 10.1007/s00432-020-03220-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
111 Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer 2017;25:1713-39. [PMID: 28224235 DOI: 10.1007/s00520-017-3629-4] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 13.0] [Reference Citation Analysis]
112 Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol 2020;13:143. [PMID: 33109256 DOI: 10.1186/s13045-020-00977-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
113 Connock M, Armoiry X, Tsertsvadze A, Melendez-Torres GJ, Royle P, Andronis L, Clarke A. Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials. BMC Cancer 2019;19:392. [PMID: 31023244 DOI: 10.1186/s12885-019-5507-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
114 Jiang H, Li X. Correlation of dual-source computed tomography/dual-energy imaging with pathological grading of lung adenocarcinoma and its clinical value. Pak J Med Sci 2017;33:1429-33. [PMID: 29492072 DOI: 10.12669/pjms.336.13320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
115 Lasala R, Santoleri F, Romagnoli A, Musicco F, Costantini A. Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. Eur J Clin Pharmacol 2019;75:697-706. [PMID: 30617511 DOI: 10.1007/s00228-018-02621-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
116 Shan G, Meihe L, Minchao K, Rui Z, Xiaopeng W, Guangjian Z, Jin Z. Identification and validation of Osteopontin and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) for potential immunotherapeutic significance of in lung squamous cell carcinoma. Int Immunopharmacol 2022;107:108715. [PMID: 35334357 DOI: 10.1016/j.intimp.2022.108715] [Reference Citation Analysis]
117 Zhu Y, Xing P, Li J. [Treatment of Advanced Squamous Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2016;19:687-91. [PMID: 27760600 DOI: 10.3779/j.issn.1009-3419.2016.10.10] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
118 Van Der Weijst L, Lievens Y, Schrauwen W, Surmont V. Health-Related Quality of Life in Advanced Non-small Cell Lung Cancer: A Methodological Appraisal Based on a Systematic Literature Review. Front Oncol 2019;9:715. [PMID: 31456938 DOI: 10.3389/fonc.2019.00715] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
119 Lee SH, Park CK, Lee SY, Choi CM. Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum-based doublet chemotherapy and immunotherapy (SPACE study). Thorac Cancer 2021;12:1264-8. [PMID: 33586312 DOI: 10.1111/1759-7714.13880] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
120 Wind S, Schnell D, Ebner T, Freiwald M, Stopfer P. Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. Clin Pharmacokinet 2017;56:235-50. [PMID: 27470518 DOI: 10.1007/s40262-016-0440-1] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 12.0] [Reference Citation Analysis]
121 Zhang SR, Zhu LC, Jiang YP, Zhang J, Xu RJ, Xu YS, Xia B, Ma SL. Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice. Acta Pharmacol Sin 2017;38:233-40. [PMID: 27840411 DOI: 10.1038/aps.2016.107] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
122 Vavalà T. Role of afatinib in the treatment of advanced lung squamous cell carcinoma. Clin Pharmacol 2017;9:147-57. [PMID: 29225480 DOI: 10.2147/CPAA.S112715] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
123 Wang TH, Leu YL, Chen CC, Shieh TM, Lian JH, Chen CY. Psorachromene Suppresses Oral Squamous Cell Carcinoma Progression by Inhibiting Long Non-coding RNA GAS5 Mediated Epithelial-Mesenchymal Transition. Front Oncol 2019;9:1168. [PMID: 31750253 DOI: 10.3389/fonc.2019.01168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
124 Köhler J. Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms. Front Med (Lausanne) 2017;4:9. [PMID: 28243590 DOI: 10.3389/fmed.2017.00009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
125 Boolell V, Alamgeer M, Watkins DN, Ganju V. The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers (Basel) 2015;7:1815-46. [PMID: 26371045 DOI: 10.3390/cancers7030864] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 9.6] [Reference Citation Analysis]
126 Yuan G, Wang L, Li J, Feng H, Ji J, Gu W, Shan B. Complexity in Clinical Trials: Blind Spots, Misleading Criteria, Winners and Losers. CCAND 2020;7:3-15. [DOI: 10.2174/2212697x06666191021125423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Gomez DR, Byers LA, Nilsson M, Diao L, Wang J, Li L, Tong P, Hofstad M, Saigal B, Wistuba I, Kalhor N, Swisher S, Fan Y, Hong WK, Suraokar M, Behrens C, Moran C, Heymach JV. Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget 2018;9:14268-84. [PMID: 29581842 DOI: 10.18632/oncotarget.24361] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
128 Yamamoto Y, Saita T, Yamamoto Y, Sogawa R, Kimura S, Narisawa Y, Kimura S, Shin M. Immunohistochemical localization of afatinib in male rat intestines and skin after its oral administration. Acta Histochem 2019;121:151439. [PMID: 31500866 DOI: 10.1016/j.acthis.2019.09.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
129 Maarof NNN, Alsalahi A, Abdulmalek E, Fakurazi S, Tejo BA, Abdul Rahman MB. Efficacy of Afatinib in the Treatment of Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:688. [PMID: 33567737 DOI: 10.3390/cancers13040688] [Reference Citation Analysis]
130 Paludan-Müller AS, Créquit P, Boutron I. Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications-a methodological review. BMC Med 2021;19:88. [PMID: 33827569 DOI: 10.1186/s12916-021-01955-0] [Reference Citation Analysis]
131 Lo Russo G, Proto C, Garassino MC. Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake? Transl Lung Cancer Res 2016;5:110-4. [PMID: 26958504 DOI: 10.3978/j.issn.2218-6751.2015.12.02] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
132 Gao X, Zhu J, Chen L, Jiang Y, Zhou X, Shuai J, Zhao Y. Clinical And Imageological Features Of Lung Squamous Cell Carcinoma With EGFR Mutations. Cancer Manag Res 2019;11:9017-24. [PMID: 31695493 DOI: 10.2147/CMAR.S223021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
133 Zhang C, Wei B, Li P, Yang K, Wang Z, Ma J, Guo Y. Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs. PLoS One 2017;12:e0173524. [PMID: 28333951 DOI: 10.1371/journal.pone.0173524] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
134 Itchins M, Clarke S, Pavlakis N. Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?-the shifting paradigm of therapeutics. Transl Lung Cancer Res 2018;7:S39-45. [PMID: 29531903 DOI: 10.21037/tlcr.2018.01.06] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
135 Ricciuti B, Baglivo S, De Giglio A, Chiari R. Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience. Ther Adv Respir Dis 2018;12:1753466618808659. [PMID: 30355049 DOI: 10.1177/1753466618808659] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
136 Zhang M, Chen H, Liang B, Wang X, Gu N, Xue F, Yue Q, Zhang Q, Hong J. Prognostic Value of mRNAsi/Corrected mRNAsi Calculated by the One-Class Logistic Regression Machine-Learning Algorithm in Glioblastoma Within Multiple Datasets. Front Mol Biosci 2021;8:777921. [PMID: 34938774 DOI: 10.3389/fmolb.2021.777921] [Reference Citation Analysis]
137 Wiebe S, Schnell D, Külzer R, Gansser D, Weber A, Wallenstein G, Halabi A, Conrad A, Wind S. Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study. Eur J Drug Metab Pharmacokinet 2017;42:461-9. [PMID: 27436099 DOI: 10.1007/s13318-016-0359-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
138 Xie X, Wang X, Wu S, Yang H, Liu J, Chen H, Ding Y, Ling L, Lin H. Fatal toxic effects related to EGFR tyrosine kinase inhibitors based on 53 cohorts with 9,569 participants. J Thorac Dis 2020;12:4057-69. [PMID: 32944317 DOI: 10.21037/jtd-19-4000A] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
139 Bhateja P, Sharma N. Afatinib plus chemotherapy versus chemotherapy alone after progression on afatinib: new insights on old question? Ann Transl Med 2016;4:S31. [PMID: 27867999 DOI: 10.21037/atm.2016.09.45] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
140 Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther 2019;4:61. [PMID: 31871778 DOI: 10.1038/s41392-019-0099-9] [Cited by in Crossref: 136] [Cited by in F6Publishing: 135] [Article Influence: 45.3] [Reference Citation Analysis]
141 Ang YL, Lim JS, Soo RA. Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. Onco Targets Ther 2016;9:3187-95. [PMID: 27313464 DOI: 10.2147/OTT.S84356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
142 Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, Cheng H, Jin K, Ni Q, Yu X, Liu C. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol 2020;13:130. [PMID: 33008426 DOI: 10.1186/s13045-020-00958-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
143 Soldera SV, Leighl NB. Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. Front Oncol 2017;7:50. [PMID: 28396848 DOI: 10.3389/fonc.2017.00050] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
144 Dotto GP, Rustgi AK. Squamous Cell Cancers: A Unified Perspective on Biology and Genetics. Cancer Cell 2016;29:622-37. [PMID: 27165741 DOI: 10.1016/j.ccell.2016.04.004] [Cited by in Crossref: 130] [Cited by in F6Publishing: 129] [Article Influence: 26.0] [Reference Citation Analysis]
145 Peng YM, Duan H, Zhang J, Sun C, Zhang X, Shen W, Zheng S, Tan K, Jiang X, Li J, Cui HJ. Application of Zizao Yangrong Granules for Treating Targeted Drugs-Related Skin Xerosis: A Randomized Double-Blinded Controlled Study. Integr Cancer Ther 2020;19:1534735420924832. [PMID: 32567372 DOI: 10.1177/1534735420924832] [Reference Citation Analysis]
146 Díaz-Serrano A, Gella P, Jiménez E, Zugazagoitia J, Paz-Ares Rodríguez L. Targeting EGFR in Lung Cancer: Current Standards and Developments. Drugs 2018;78:893-911. [PMID: 29915896 DOI: 10.1007/s40265-018-0916-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
147 Thongprasert S, Geater SL, Clement D, Abdelaziz A, Reyes-Igama J, Jovanovic D, Alexandru A, Schenker M, Sriuranpong V, Serwatowski P, Suresh S, Cseh A, Gaafar R. Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study. Lung Cancer Manag 2019;8:LMT15. [PMID: 31807143 DOI: 10.2217/lmt-2019-0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
148 Zhang J, Zhang Y, Tang S, Liang H, Chen D, Jiang L, He Q, Huang Y, Wang X, Deng K, Jiang S, Zhou J, Xu J, Chen X, Liang W, He J. Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years. Ann Transl Med 2017;5:481. [PMID: 29299443 DOI: 10.21037/atm.2017.11.24] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
149 Santos ES, Hart L. Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib. Onco Targets Ther 2020;13:9305-21. [PMID: 33061419 DOI: 10.2147/OTT.S250446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
150 Ichiki M, Wataya H, Yamada K, Tsuruta N, Takeoka H, Okayama Y, Sasaki J, Hoshino T. Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer. Onco Targets Ther 2017;10:5107-13. [PMID: 29123409 DOI: 10.2147/OTT.S145613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
151 Qian J, Zhang X, Zhang B, Gu P, Wang L, Han B. Hepatotoxicity in Advanced Lung Adenocarcinoma: A Retrospective Study of 2108 Cases. J Cancer 2018;9:1607-13. [PMID: 29760799 DOI: 10.7150/jca.24217] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
152 Zhang YC, Zhou Q, Wu YL. Emerging challenges of advanced squamous cell lung cancer. ESMO Open 2016;1:e000129. [PMID: 28255454 DOI: 10.1136/esmoopen-2016-000129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
153 Xu Y, Ding VW, Zhang H, Zhang X, Jablons D, He B. Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far. Ther Clin Risk Manag 2016;12:807-16. [PMID: 27307741 DOI: 10.2147/TCRM.S92996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
154 Jian H, Han Y, Yu Y, Lu S. Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma. Anticancer Drugs 2019;30:873-8. [PMID: 31283542 DOI: 10.1097/CAD.0000000000000813] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
155 Spira A, Halmos B, Powell CA. Update in Lung Cancer 2015. Am J Respir Crit Care Med 2016;194:661-71. [PMID: 27628077 DOI: 10.1164/rccm.201604-0898UP] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
156 Jobe AL, Ahonen KT, Poplin V, Rao S, Mohyuddin GR. Afatinib-induced Interstitial Lung Disease Successfully Treated with Corticosteroids: Case Report and Review of the Literature. Cureus 2018;10:e2805. [PMID: 30123727 DOI: 10.7759/cureus.2805] [Reference Citation Analysis]
157 Houron C, Danielou M, Mir O, Fromenty B, Perlemuter G, Voican CS. Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians. Crit Rev Oncol Hematol 2021;157:103127. [PMID: 33161366 DOI: 10.1016/j.critrevonc.2020.103127] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
158 Yang L, Lin S, Kang Y, Xiang Y, Xu L, Li J, Dai X, Liang G, Huang X, Zhao C. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway. J Exp Clin Cancer Res 2019;38:31. [PMID: 30674340 DOI: 10.1186/s13046-018-1015-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
159 Han L, Zhang X, Wang Z, Zhang X, Zhao L, Fu W, Liang X, Zhang Z, Wang Y. SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer. Front Pharmacol 2021;12:665253. [PMID: 33986687 DOI: 10.3389/fphar.2021.665253] [Reference Citation Analysis]
160 Fan L, Yang H, Yao F, Zhao Y, Gu H, Han K, Zhao H. Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection. Onco Targets Ther 2017;10:239-45. [PMID: 28123305 DOI: 10.2147/OTT.S114451] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
161 Berghoff AS, Preusser M. New developments in brain metastases. Ther Adv Neurol Disord 2018;11:1756286418785502. [PMID: 30034538 DOI: 10.1177/1756286418785502] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
162 Xu X, Fang N, Li H, Liu Y, Yang F, Li X. Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China. Ann Transl Med 2021;9:760. [PMID: 34268373 DOI: 10.21037/atm-20-6992] [Reference Citation Analysis]
163 Hu M, Zhang B, Xu J, Wang S, Zhao Y, Zhang L, Han B. Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma. Mol Diagn Ther 2019;23:773-9. [PMID: 31713818 DOI: 10.1007/s40291-019-00425-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
164 Yu J, Fang T, Yun C, Liu X, Cai X. Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Front Mol Biosci 2022;9:847835. [DOI: 10.3389/fmolb.2022.847835] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Sun M, Guo Y, Wang X, Sun C, Shao J, Xu Y, Qiu S, Ma K. Long-term response to second-line afatinib treatment for advanced squamous cell carcinoma non-small cell lung cancer: a rare case report. J Int Med Res 2020;48:300060520964700. [PMID: 33115309 DOI: 10.1177/0300060520964700] [Reference Citation Analysis]
166 Liang S, Xu Y, Tan F, Ding L, Ma Y, Wang M. Efficacy of icotinib in advanced lung squamous cell carcinoma. Cancer Med 2018;7:4456-66. [PMID: 30109777 DOI: 10.1002/cam4.1736] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
167 Goss GD, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Isla D, Morabito A, Min YJ, Ardizzoni A, Bender S, Cseh A, Felip E. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. EClinicalMedicine 2021;37:100940. [PMID: 34195574 DOI: 10.1016/j.eclinm.2021.100940] [Reference Citation Analysis]
168 Pirker R, Filipits M. Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice. Cancer Metastasis Rev 2016;35:141-50. [PMID: 26970967 DOI: 10.1007/s10555-016-9612-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]